利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.02 秒)

    Bis-acridone chemotherapeutic derivatives
    4.
    发明授权
    Bis-acridone chemotherapeutic derivatives 失效
    双吖啶酮化疗衍生物

    公开(公告)号：US5508289A

    公开(公告)日：1996-04-16

    申请号：US213315

    申请日：1994-03-14

    申请人： Christopher J. Michejda ,  Wieslaw M. Cholody ,  Lidia Hernandez

    发明人： Christopher J. Michejda ,  Wieslaw M. Cholody ,  Lidia Hernandez

    IPC分类号： G01N33/50 ,  A61K31/435 ,  A61K31/47 ,  A61K31/473 ,  A61K49/00 ,  A61P35/02 ,  C07D219/06 ,  C07D219/08 ,  C07D471/06 ,  C07D519/00 ,  C07H21/00 ,  A61K31/41 ,  C07D471/00 ,  C07D487/02

    CPC分类号： A61K49/0026 ,  C07D219/08

    摘要： The present invention provides an anticancer compound having the structure: ##STR1## wherein R is --H, --CH.sub.3, or --C.sub.2 H.sub.5 ; R1 and R2 are independently --H, --OH, --NH.sub.2, --OCH.sub.3, --C(CH.sub.3).sub.3, or a halogen atom; n is 2 to 6; X and X' are independently --N or --NO.sub.2 ; Y and Y' are independently --N, --CH, or --H; and the double-slash represents a double bond or no bond; such that when X or X' is --N, Y or Y' is --CH or --N, and the double-slash is a double bond, and when X or X' is --NO.sub.2, Y or Y' is --H, and the double-slash is no bond. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供具有以下结构的抗癌化合物：其中R为-H，-CH 3或-C 2 H 5; R 1和R 2独立地是-H，-OH，-NH 2，-OCH 3，-C（CH 3）3或卤素原子; n为2〜6; X和X'独立地是-N或-NO 2; Y和Y'独立地是-N，-CH或-H; 双斜杠代表双键或无键; 使得当X或X'为-N时，Y或Y'为-CH或-N，双斜线为双键，当X或X'为-NO 2时，Y或Y'为-H， 而双斜杠是没有纽带的。 本发明还提供包含上述化合物和药学上可接受的载体的药物组合物。

    AZO COMPOUNDS FOR TYPE I PHOTOTHERAPY
    6.
    发明申请
    AZO COMPOUNDS FOR TYPE I PHOTOTHERAPY 失效
    用于I型照相机的AZO化合物

    公开(公告)号：US20020164287A1

    公开(公告)日：2002-11-07

    申请号：US09849163

    申请日：2001-05-04

    申请人： MALLINCKRODT INC.

    发明人： Raghavan Rajagopalan ,  Gary L. Cantrell ,  Joseph E. Bugaj ,  Samuel I. Achilefu ,  Richard B. Dorshow

    IPC分类号： A61K049/00 ,  C08B037/00 ,  A61K039/395

    CPC分类号： A61K49/0026 ,  A61K41/0057 ,  A61K47/64 ,  A61K49/0039 ,  A61K49/0041 ,  A61K49/0056 ,  C07D471/06

    摘要： Novel azo compounds and their bioconjugates for phototherapy and/or photodiagnosis of tumors and other lesions. The azo derivatives of the present invention are designed to absorb at the low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photoexcitation of the azo compound, with the tissue of interest.

    摘要翻译： 新型偶氮化合物及其生物缀合物用于光疗和/或光化学诊断肿瘤和其他病变。 本发明的偶氮衍生物被设计成在电磁光谱的低能量紫外线，可见光或近红外（NIR）区域吸收。 光疗效果是由自由基（通过偶氮化合物的光激发产生的反应性中间体）与感兴趣的组织的直接相互作用引起的。

    Composition for diagnosing the transport function of the fallopian tube and a method for preparing said composition
    8.
    发明授权
    Composition for diagnosing the transport function of the fallopian tube and a method for preparing said composition 失效
    用于诊断输卵管的运输功能的组合物和制备所述组合物的方法

    公开(公告)号：US4808399A

    公开(公告)日：1989-02-28

    申请号：US940300

    申请日：1986-12-11

    申请人： Frantisek Rypacek ,  Jan Uher ,  Jaroslav Drobnik

    发明人： Frantisek Rypacek ,  Jan Uher ,  Jaroslav Drobnik

    IPC分类号： A61K49/00 ,  A61K9/22 ,  A61K9/24 ,  A61K9/26 ,  A61K9/52 ,  G01N1/00 ,  G01N3/48

    CPC分类号： A61K49/0043 ,  A61K49/0026 ,  A61K49/0041 ,  A61K49/006 ,  A61K49/0091 ,  Y10S514/953 ,  Y10S514/964

    摘要： The present invention pertains to a preparation for diagnosing the transport function of the fallopian tube and to a method for making such a preparation.The diagnostic preparation for investigation of the transport function of female fallopian tube, comprises a suspension of a biocompatible, biodegradable, and, if desired, labelled particles, in a vehicle commonly used for parenteral applications wherein the particles have a spherical shape with diameters in the region 10 to 600 um, which are formed from a soft hydrophilic gel based on a polymer selected from the group comprising additionally crosslinked water-soluble nontoxic and biodegradable inert polysaccharides and physiologically inert water-soluble and biodegradable poly(amino acids), polypeptides, and their derivatives, which may contain physiologically active substances. The particles retain their shape and size in the environment of peritoneal cavity and uterotubal tract for at least 80 hours with the subsequent degradation to nontoxic product within 5 to 60 days.A method for preparation of the diagnostic preparation comprises dispersing an aqueous solution of physilogically inert, biodegradable polymer selected from the group of polysaccharides, poly(amino acids), polypeptides, and their derivatives, in a medium of nonpolar water-immiscible solvent, to 10 wt. % of the polymer having a degree of polymerization of 50 to 500, said suspension containing of 80 to 100 mol. % of .gamma.-alkyl-L-glutamate units and 0 to 20 mol. % units of L-glutamic acid, units as a suspension stabilizer, with mixing sufficient to form polymeric spherical particles with diameter 100 to 600 um, which are transferred into the gel state with bifunctional crosslinking agents. The particles are washed and then dispersed in an aqueous solution. The resulting suspension is then sterilized by heat.

    摘要翻译： 本发明涉及用于诊断输卵管的输送功能的制剂及其制备方法。 女性输卵管的运输功能调查的诊断准备包括生物相容的，可生物降解的和如果需要的标记的颗粒的悬浮液，其通常用于肠胃外应用的载体中，其中颗粒具有直径在 区域10至600μm，其由基于选自另外交联的水溶性无毒和可生物降解的惰性多糖和生理惰性水溶性和可生物降解的聚（氨基酸）多肽和多肽的聚合物的柔性亲水性凝胶形成， 其衍生物，其可以含有生理活性物质。 颗粒在腹膜腔和子宫腔的环境中保持其形状和尺寸至少80小时，随后在5至60天内降解无毒产品。 制备诊断制剂的方法包括将选自多糖，多（氨基酸），多肽及其衍生物的物理惰性，可生物降解的聚合物的水溶液分散在非极性水不混溶溶剂的介质中，至10 重量 聚合度为50〜500的聚合物的％，所述悬浮液含有80〜100摩尔。 ％的γ-烷基-L-谷氨酸单元和0至20mol。 混合物的L-谷氨酸单位为悬浮稳定剂，其混合足以形成直径为100至600μm的聚合物球形颗粒，其用双功能交联剂转移到凝胶状态。 将颗粒洗涤然后分散在水溶液中。 然后将所得悬浮液加热灭菌。